CN110433236A - 一种促进伤口愈合的中药组合物及其制备方法和应用 - Google Patents
一种促进伤口愈合的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN110433236A CN110433236A CN201910667761.5A CN201910667761A CN110433236A CN 110433236 A CN110433236 A CN 110433236A CN 201910667761 A CN201910667761 A CN 201910667761A CN 110433236 A CN110433236 A CN 110433236A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- chinese medicine
- chinese
- wound healing
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000029663 wound healing Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims abstract description 23
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 20
- 244000157790 Buglossoides arvense Species 0.000 claims abstract description 19
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 19
- 208000002193 Pain Diseases 0.000 claims abstract description 19
- 230000036407 pain Effects 0.000 claims abstract description 19
- 240000004824 Trimezia steyermarkii Species 0.000 claims abstract description 17
- 239000009136 dragon's blood Substances 0.000 claims abstract description 17
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 14
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052709 silver Inorganic materials 0.000 claims abstract description 13
- 239000004332 silver Substances 0.000 claims abstract description 13
- 241000125175 Angelica Species 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 16
- 239000002398 materia medica Substances 0.000 claims description 9
- 230000001114 myogenic effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 231100000614 poison Toxicity 0.000 claims description 5
- 239000003440 toxic substance Substances 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000013583 drug formulation Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 229940043263 traditional drug Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- -1 pulvis Substances 0.000 claims 1
- 238000005469 granulation Methods 0.000 abstract description 11
- 230000003179 granulation Effects 0.000 abstract description 11
- 241000222122 Candida albicans Species 0.000 abstract description 9
- 241000588724 Escherichia coli Species 0.000 abstract description 9
- 229940095731 candida albicans Drugs 0.000 abstract description 9
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 5
- 244000052769 pathogen Species 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 38
- 206010052428 Wound Diseases 0.000 description 37
- 241000700159 Rattus Species 0.000 description 29
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 8
- 229960002591 hydroxyproline Drugs 0.000 description 8
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 8
- 206010063560 Excessive granulation tissue Diseases 0.000 description 6
- 210000001126 granulation tissue Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001416180 Moschidae Species 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种促进伤口愈合的中药组合物及其制备方法和应用。按照重量百分比计,本发明的中药组合物是由40‑50%血竭、5‑10%麝香、20‑30%白芷、20‑30%紫草以及银离子组成,其中每克中药组合物中含银量不少于100μg。实验证明,本发明的中药组合物具有清热解毒、创面愈合、生肌定痛的功效,可抑制大肠杆菌、金黄色葡萄球菌、白色念珠菌等多种致病菌生长,缓解疮口疼痛、促进新肉生长、加速愈合,治愈率高且合成简单,有利于推广生产和应用。
Description
技术领域
本发明涉及一种中药组合物及其制备方法和应用,特别涉及一种由银离子、血竭、白芷、紫草、麝香5种中药组成的中药组合物,及其在生肌定痛促进伤口愈合中的用途。本发明属于医药技术领域。
背景技术
创伤修复过程可大致分为局部炎症反应、细胞增殖和组织重建3个阶段。胶原是创面组织中的主要基质成分,由于胶原成分中羟脯氨酸含量较为固定,故创面组织中羟脯氨酸的含量不仅可显示愈合的速度,也可以标志愈合的质量。组织修复过程中,由于创面细胞增殖和组织再生,加速了创面处的新陈代谢,使得创面局部温度上升。因此局部温度升高情况可以直接反映伤口愈合速度。创口感染是组织愈合缓慢及产生疼痛的重要原因,现有研究表明创口感染多是由金黄色葡萄球菌、大肠杆菌、白色念球菌等致病菌导致,故检测创口中金黄色葡萄球菌、大肠杆菌、白色念球菌数目可直接反映创口感染程度。
银离子作为抑菌剂的使用可以追溯到19世纪,具有损伤细菌细胞壁、抑制细菌蛋白质合成的功效。银离子对液体中的微生物具有吸附作用,微生物被银吸附后,可使起呼吸作用的酶失去功效,导致微生物的迅速死亡。银离子自身可杀毒多达650种,对大肠杆菌、金黄色葡萄球菌、白色念球菌等杀灭效果更为显著。
血竭是由棕榈科植物麒麟竭果实渗出的树脂经加工制成,味甘、咸,性平。具有散瘀定痛、止血、生肌敛疮的功效。主治跌打损伤、内伤瘀痛、痛经、产后瘀阻腹痛、外伤出血不止、瘰疬、臁疮溃久不合及痔疮。内服活血散瘀止痛:可用于外伤瘀痛,筋骨伤痛,血瘀痛经,产后瘀阻腹痛及血瘀心腹诸痛。外用止血生肌敛疮:善治痈疽恶疮,久不收口,及外伤出血。改善血液循环系统,促使血液黏稠度变低,有效地阻滞血小板的聚集反应。动物实验证实具有抗多种致病菌及止血作用。
白芷和紫草均有清热解毒、活血利湿的功效。白芷是多年生高大草本,性温,味辛,气芳香,微苦。以根入药,有祛病除湿、排脓生肌、活血止痛等功能。《纲目》谓:“白芷,色白味辛,风热者辛以散之,湿热者温以除之。为阳明主药,故又能治血病、胎病,而排脓生肌止痛。”紫草具有凉血,活血,清热,解毒。治温热斑疹,湿热黄疸,紫癜,吐、衄、尿血,淋浊,热结便秘,烧伤,湿疹,丹毒,痈疡功效。《本草图经》曾有记载:"治伤寒时疾,发疮疹不出者,以此作药,使其发出。"白芷和紫草均可以通过刺激生长因子分泌,对创面修复具有显著促进作用。
麝香为雄麝的肚脐和生殖器之间腺囊的分泌物,干燥后保存,呈颗粒状或块状,有特殊的香气。麝香性温、辛,味苦,无毒,有开窍辟秽,通络散瘀之功能。主治中风、痰厥、惊痫、中恶烦闷、心腹暴痛、跌打损伤、痈疽肿毒。麝香药用始载于《神龙本草经》,历代本草均予收载,均主要述其芳香开窍之功,《医学入门》中介绍麝香可通关透窍,上达肌肉,内入骨髓。在民间,用包过麝香的纸敷于伤口治疗疮疡和刀伤,止血和止痛效果非常明显。其所含有的肽、氨基酸、大环化活物、性激素和多种微量元素在伤口的愈合过程中的胶原合成环节起到催化酶的作用。麝香具有较强的抗炎作用,其抗炎作用是糖皮质激素的数十倍。另外,麝香可促进血管新生,加快创面处血管增生和血液供应,提高局部温度,加速创面愈合。
本发明注重中医理论,诸药配合具有生肌敛疮、消肿止痛、抑菌解毒的功效,能够有效减轻疼痛、促进伤口愈合。
发明内容
本发明所要解决的技术问题是提供一种具有生肌敛疮、消肿止痛、抑菌解毒的功效,能够有效减轻疼痛、促进伤口愈合的中药组合物及其制备方法和应用。
为了达到上述目的,本发明采用了以下技术手段:
本发明的一种一种促进伤口愈合的中药组合物,按照重量百分比计,所述的中药组合物由40-50%血竭、5-10%麝香、20-30%白芷、20-30%紫草以及银离子组成,其中每克中药组合物中含银量不少于100μg。
其中,优选的,按照重量百分比计,所述的中药组合物由45%血竭、10%麝香、25%白芷、20%紫草以及银离子组成,其中每克中药组合物中含银量为150μg。
将本发明的中药组方敷在大鼠背部正中距脊柱0.5cm的深达皮下筋膜层纵向线性切口上,对照组大鼠只造模,不给药。实验期间每天换药一次,通过大量的实验证实该组合物可加快大鼠伤口处上皮出现的时间,缩短伤口愈合时间,提高大鼠伤口肉芽组织中的羟脯氨酸含量,升高大鼠伤口肉芽温度与周围皮肤温度差值,降低伤口大肠杆菌、金黄色葡萄球菌、白色念球菌等致病菌感染几率。
因此,进一步的,本发明还提出了所述的中药组合物在制备具有生肌敛疮、消肿止痛、抑菌解毒的功效,能够有效减轻疼痛、促进伤口愈合的中药制剂中的用途。
更进一步的,本发明还提出了一种制备所述的中药组合物的方法,包括以下步骤:
(1)将血竭、白芷、紫草、麝香研磨后过筛;
(2)按照本发明所述的重量百分比分别称取血竭、麝香、白芷、以及紫草,均匀混合,各组分的重量百分比之和等于100%,加水煎煮3次,每次2小时,合并3次过滤液;
(3)加入银离子,浓缩至每毫升相当于1g生药,每克中药组合物中含银量不少于100μg,优选的,其中每克中药组合物中含银量为150μg。
一种促进伤口愈合的中药制剂,其是向所述的中药组合物中加入药学上接受辅料,按照常规药物制剂的制备方法制成各种中药制剂。
其中,优选的,所述的中药制剂包括水煎剂、片剂、颗粒剂、粉剂、胶囊剂或口服液。
相较于现有技术,本发明的有益效果是:
本发明提出了一种促进伤口愈合的中药组合物及其制备方法,实验证明,该中药混合物具有清热解毒、创面愈合、生肌定痛的功效,可抑制大肠杆菌、金黄色葡萄球菌、白色念珠菌等多种致病菌生长,缓解疮口痛疼,促进新肉生长,加速疮口愈合,治愈率高且安全无副作用。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
实施例1、中药组合物的制备
(1)将血竭、白芷、紫草、麝香研磨后过筛;
(2)按照重量百分比分别称取45%血竭、10%麝香、25%白芷、20%紫草,将称取的药物均匀混合,加水煎煮3次,每次2小时,合并3次过滤液;
(3)加入银离子,浓缩至每毫升相当于1g生药,每克中药组合物中含银量为150μg。
实施例2、中药组合物的制备
(1)将血竭、白芷、紫草、麝香研磨后过筛;
(2)按照重量百分比分别称取50%血竭、5%麝香、25%白芷、20%紫草,将称取的药物均匀混合,加水煎煮3次,每次2小时,合并3次过滤液;
(3)加入银离子,浓缩至每毫升相当于1g生药,每克中药组合物中含银量为100μg。
实施例3、中药组合物的制备
(1)将血竭、白芷、紫草、麝香研磨后过筛;
(2)按照重量百分比分别称取40%血竭、10%麝香、25%白芷、25%紫草,将称取的药物均匀混合,加水煎煮3次,每次2小时,合并3次过滤液;
(3)加入银离子,浓缩至每毫升相当于1g生药,每克中药组合物中含银量为200μg。
实施例4、中药组合物促进伤口愈合的药效试验
1、大鼠伤口造模的制备和创面给药方法
采用体重约为200g的清洁级SD大鼠,雌雄各半,用8%的硫化钠脱去大鼠背部4*4cm区域的毛,在大鼠背部无毛区域用剪刀剪去直径3cm的圆形全层皮肤、深达筋膜,止血后创面。对照组:伤口涂以碘酒;阳性药组:伤口涂抹常用的创伤药“莫匹罗星软膏”(百多邦);实验组:伤口均匀敷上中药组合物(实施例1制备),覆盖全伤口。每两天换一次药。
2、中药组合物抑制大鼠的伤口细菌感染
治疗1天后,用消毒棉签分别蘸取大肠杆菌、金黄色葡萄球菌、白色念珠菌菌液涂在创面上,再继续治疗4天后,观察对照组、阳性药组和中药组合物给药组大鼠创面的感染情况,活检取材进行细菌计数。比较对照组、阳性药组和中药组合物给药组大鼠细菌生长速度,检测结果显示中药组合物给药组大鼠伤口的大肠杆菌、金黄色葡萄球菌、白色念珠菌生长速度明显下降,结果如表1所示。
表1中药组合物对大鼠伤口细菌感染的影响
注:给药组与对照组比较,**P<0.01
3、中药组合物缩短创面上皮出现时间
记录对照组、阳性药组和中药组合物给药组大鼠创面出现上皮的时间,并计算上皮出现的平均时间,结果如表2所示。
表2中药组合物对大鼠伤口出现上皮的平均时间的影响
注:实验组与对照组比较,**P<0.01
4、中药组合物缩短伤口愈合时间
记录对照组、阳性药组和中药组合物实验组大鼠创面愈合时间,并计算伤口愈合的平均时间,结果如表3所示。
表3中药组合物对大鼠伤口愈合的平均时间的影响
注:实验组与对照组比较,**P<0.01
5、中药组合物提高大鼠第7、14天的伤口愈合面积百分比
分别在第7、14天计算大鼠伤口愈合率,结果如表4所示。
表4中药组合物第7天和第14天对大鼠伤口愈合面积百分比的影响
注:实验组与对照组比较,**P<0.01
6、中药组合物提高大鼠伤口肉芽组织中的羟脯氨酸含量
利用羟脯氨酸标准液对制定羟脯氨酸含量标准曲线,分别提取单位重量的对照组、阳性药组和中药组合物实验组大鼠创面肉芽组织,并提取羟脯氨酸,进行721分光光度计比色,计算每克肉芽组织中羟脯氨酸含量毫克数。检测结果显示在第7、14天,中药组合物实验组大鼠的肉芽组织中羟脯氨酸含量明显升高,结果如表5所示。
表5大鼠创面组织羟脯氨酸含量的影响
注:实验组与对照组比较,**P<0.01
7、中药组合物升高大鼠伤口肉芽温度与周围皮肤温度差值
分别在第7、14检测对照组、阳性药组和中药组合物实验组大鼠伤口肉芽温度与周围皮肤温度,并计算两者差值,比较对照组、阳性药组和中药组合物实验组的差值,检测结果显示中药组合物实验组大鼠的伤口肉芽温度与周围皮肤温度差值明显升高,结果如表6所示。
表6中药组合物对大鼠伤口肉芽组织温度与周围皮肤温度差值的影响
注:实验组与对照组比较,**P<0.01
以上实验证明,本发明的中药组合物可抑制大肠杆菌、金黄色葡萄球菌、白色念珠菌等多种致病菌生长,缓解疮口痛疼,促进新肉生长,加速疮口愈合,且安全无副作用。
Claims (6)
1.一种促进伤口愈合的中药组合物,其特征在于,按照重量百分比计,所述的中药组合物由40-50%血竭、5-10%麝香、20-30%白芷、20-30%紫草以及银离子组成,其中每克中药组合物中含银量不少于100μg。
2.如权利要求1所述的中药组合物,其特征在于,按照重量百分比计,所述的中药组合物由45%血竭、10%麝香、25%白芷、20%紫草以及银离子组成,其中每克中药组合物中含银量为150μg。
3.权利要求1或2所述的中药组合物在制备具有生肌敛疮、消肿止痛、抑菌解毒的功效,能够有效减轻疼痛、促进伤口愈合的中药制剂中的用途。
4.一种制备权利要求1或2所述的中药组合物的方法,其特征在于,包括以下步骤:
(1)将血竭、白芷、紫草、麝香研磨后过筛;
(2)按照权利要求1或2所述的重量百分比分别称取血竭、麝香、白芷、以及紫草,均匀混合,各组分的重量百分比之和等于100%,加水煎煮3次,每次2小时,合并3次过滤液;
(3)加入银离子,浓缩至每毫升相当于1g生药,每克中药组合物中含银量不少于100μg,优选的,其中每克中药组合物中含银量为150μg。
5.一种促进伤口愈合的中药制剂,其特征在于,向权利要求1或2所述的中药组合物中加入药学上接受辅料,按照常规药物制剂的制备方法制成各种中药制剂。
6.如权利要求5所述的中药制剂,其特征在于,所述的中药制剂包括水煎剂、片剂、颗粒剂、粉剂、胶囊剂或口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910667761.5A CN110433236B (zh) | 2019-07-23 | 2019-07-23 | 一种促进伤口愈合的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910667761.5A CN110433236B (zh) | 2019-07-23 | 2019-07-23 | 一种促进伤口愈合的中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110433236A true CN110433236A (zh) | 2019-11-12 |
CN110433236B CN110433236B (zh) | 2021-09-03 |
Family
ID=68431300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910667761.5A Active CN110433236B (zh) | 2019-07-23 | 2019-07-23 | 一种促进伤口愈合的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110433236B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1055297A (zh) * | 1991-03-28 | 1991-10-16 | 许聿祥 | 一种润肤烧烫药物的制造法 |
CN1714838A (zh) * | 2005-06-17 | 2006-01-04 | 吴湘君 | 医用凝胶及其制备方法和设备 |
CN101791364A (zh) * | 2010-04-28 | 2010-08-04 | 董崇孝 | 一种促进伤口愈合的中药组合物及其制备方法 |
CN102266583A (zh) * | 2011-07-10 | 2011-12-07 | 东华大学 | 一种载银改性细菌纤维素基复配功能湿态敷料的制备方法 |
RU2011118785A (ru) * | 2011-05-12 | 2012-11-20 | Учреждение Российской академии наук Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН | Коллоидный раствор наночастиц серебра, металл-полимерный нанокомпозитный пленочный материал, способы их получения, бактерицидный состав на основе коллоидного раствора и бактерицидная пленка из металл-полимерного материала |
US20160243164A1 (en) * | 2011-05-05 | 2016-08-25 | Celacare Technologies, Llc | Antimicrobial silver hydrogel composition for the treatment of burns and wounds |
CN107982387A (zh) * | 2017-12-11 | 2018-05-04 | 高金水 | 一种治疗烫伤的中药组合物及其制备方法 |
WO2018146504A1 (en) * | 2017-02-09 | 2018-08-16 | Elamin Ihsan Mohammed Elhadi | Potentiality of lagenaria siceraria ointment for diabetic wound healing |
CN108578540A (zh) * | 2018-06-05 | 2018-09-28 | 深圳市旷逸生物科技有限公司 | 一种抑制疤痕和促进伤口愈合的生物配方及其制备方法 |
-
2019
- 2019-07-23 CN CN201910667761.5A patent/CN110433236B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1055297A (zh) * | 1991-03-28 | 1991-10-16 | 许聿祥 | 一种润肤烧烫药物的制造法 |
CN1714838A (zh) * | 2005-06-17 | 2006-01-04 | 吴湘君 | 医用凝胶及其制备方法和设备 |
CN101791364A (zh) * | 2010-04-28 | 2010-08-04 | 董崇孝 | 一种促进伤口愈合的中药组合物及其制备方法 |
US20160243164A1 (en) * | 2011-05-05 | 2016-08-25 | Celacare Technologies, Llc | Antimicrobial silver hydrogel composition for the treatment of burns and wounds |
RU2011118785A (ru) * | 2011-05-12 | 2012-11-20 | Учреждение Российской академии наук Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН | Коллоидный раствор наночастиц серебра, металл-полимерный нанокомпозитный пленочный материал, способы их получения, бактерицидный состав на основе коллоидного раствора и бактерицидная пленка из металл-полимерного материала |
CN102266583A (zh) * | 2011-07-10 | 2011-12-07 | 东华大学 | 一种载银改性细菌纤维素基复配功能湿态敷料的制备方法 |
WO2018146504A1 (en) * | 2017-02-09 | 2018-08-16 | Elamin Ihsan Mohammed Elhadi | Potentiality of lagenaria siceraria ointment for diabetic wound healing |
CN107982387A (zh) * | 2017-12-11 | 2018-05-04 | 高金水 | 一种治疗烫伤的中药组合物及其制备方法 |
CN108578540A (zh) * | 2018-06-05 | 2018-09-28 | 深圳市旷逸生物科技有限公司 | 一种抑制疤痕和促进伤口愈合的生物配方及其制备方法 |
Non-Patent Citations (2)
Title |
---|
叶谢智华: "烫疮油治疗火器伤伤口临床疗效观察", 《上海中医药杂志》 * |
贾俊海: "生肌玉红膏治疗截趾术后伤口组织血运性坏死2例报告 ", 《甘肃中医》 * |
Also Published As
Publication number | Publication date |
---|---|
CN110433236B (zh) | 2021-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101543565B (zh) | 一种治疗外科伤口感染的中药外用制剂药品及制造方法 | |
CN1593540A (zh) | 一种治疗烧烫伤的药物及其制备方法 | |
CN111297961A (zh) | 一种促进伤口愈合的侗药 | |
CN102526411A (zh) | 一种治疗外科伤口的中药组合物 | |
CN106581439A (zh) | 一种治疗创伤、糖尿病足和皮肤溃烂的中药组合物及其制备方法 | |
WO2012100754A1 (zh) | 一种治疗刀伤、烧伤及多种创伤中药组合物 | |
CN101332271A (zh) | 一种治疗烧烫伤的外用药物组合物 | |
CN114931611B (zh) | 一种治疗烧烫伤、创伤病症的中药组合物及其制备方法 | |
CN105560620A (zh) | 一种用于外伤处理的中药制剂 | |
CN113262264A (zh) | 一种用于止痛生肌的中药组合物及其制备方法 | |
CN110433236A (zh) | 一种促进伤口愈合的中药组合物及其制备方法和应用 | |
CN107397886A (zh) | 用于防治仔猪红痢的中药组合物及其制备方法和应用 | |
CN106491568A (zh) | 一种治疗皮肤外伤及感染的海洋生物喷膜及其制备方法 | |
CN103142727B (zh) | 治疗人体烧烫伤的中草药组合物 | |
CN112156225A (zh) | 一种壳聚糖或和海藻多糖复合生物基质液体敷料凝胶制剂及其制备方法 | |
CN110624032A (zh) | 一种治疗烧烫伤的膏剂及其制备方法 | |
CN114010704B (zh) | 用于治疗疮疡类疾病的外用中药组合物、药线及制备方法 | |
CN104623304A (zh) | 一种治疗湿热毒蕴型慢性皮肤溃疡的洗剂及其制备方法 | |
CN112870293A (zh) | 一种外伤用中药组合物及其应用 | |
CN1686343A (zh) | 一种抗菌生肌的中药制剂 | |
CN103893422B (zh) | 修复皮肤损伤的药物及其制备方法 | |
CN114796322B (zh) | 一种治疗跌打肿痛的中药制剂及其制备方法 | |
CN114848778B (zh) | 一种消炎止痛促进创伤愈合的复方箍围膏及其制备方法和应用 | |
CN109464534B (zh) | 防治烧烫伤的组合物及其制备方法 | |
CN105213732A (zh) | 一种褥疮膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |